It is worth noting that although this tumor was progressing on the PD1 inhibitor pembrolizumab (Table 1), this patient had progressed on prior BRAF/MEK inhibitor combination therapy, presumably due to the activating NRAS Q22K mutation. Here, NRAS is linked to neoplasm.